Securities code: Beijing Scitop Bio-Tech Co.Ltd(300858) securities abbreviation: Beijing Scitop Bio-Tech Co.Ltd(300858) Announcement No.: 2022017 Beijing Scitop Bio-Tech Co.Ltd(300858) 2021 annual report summary I. important tips the summary of this annual report is from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should carefully read the full text of the annual report in the media designated by the CSRC. In addition to the following directors, other directors attended the meeting of the board of directors to consider the annual report in person
Name of director not present in person position of director not present in person reason for not attending the meeting name of the entrusted person
The audit opinion of Zhongshen Zhonghuan Certified Public Accountants (special general partnership) on the company’s financial report this year is: standard unqualified opinion. Changes of accounting firm during the reporting period: the accounting firm of the company changed from Zhongshen Zhonghuan accounting firm (special general partnership) to Zhongshen Zhonghuan accounting firm this year. Tips on non-standard audit opinions □ applicable √ not applicable the company was not profitable at the time of listing and is not profitable at present □ applicable √ not applicable to the profit distribution plan of common stock or the plan of converting accumulation fund into share capital in the reporting period considered by the board of directors √ applicable □ not applicable
The company’s profit distribution plan for ordinary shares reviewed and approved by the board of directors is: Based on the total share capital of 148531845 shares as of December 31, 2021, distribute cash dividends of 5.00 yuan (including tax) to all shareholders for every 10 shares, give bonus shares of 0 shares (including tax), and transfer capital reserve to all shareholders for every 10 shares.
Preferred stock profit distribution plan for the reporting period adopted by the board of directors □ applicable √ not applicable II. Basic information of the company 1. Company profile
Stock code
Shenzhen Stock Exchange
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Zhang Lingyu, Xie Ling
Office address: No. 31, Funiu River Road, Yanqi Economic Development Zone, Huairou District, Beijing No. 1-2, courtyard 1-2, No. 31, Funiu River Road, Yanqi Economic Development Zone, Huairou District, Beijing
Fax: 01069667381
Tel: 0106966738901069667389
E-mail [email protected]. [email protected].
2. Introduction to main business or products during the reporting period
The company’s long-term strategic goal is to become “the first brand of probiotics in China and the leading enterprise of food ingredients”. The company’s vision is to “source from nature and deliver health”. Since its establishment in 2003, the company has long focused on the research and development of food formula, compound food additive formula and corresponding process technology, has long been engaged in the production and sales of compound food additives, and provides customers with a complete set of product solutions. The company has formed the layout of the whole industrial chain of probiotics, developed probiotics more suitable for Chinese intestinal health, and become one of the few listed enterprises in the field of probiotics in China.
(I) overview of main business
The company’s main business is the R & D, production and sales of compound food additives, edible probiotic products and animal and plant probiotics. The company’s products are widely used in food industry, health care, animal husbandry, agricultural planting and other fields, and provide product completion solutions for downstream customers. During the reporting period, there was no significant change in the company’s main business. The production and sales business of edible probiotic products of the company started relatively late. However, due to the profound accumulation of technology research and development over the years, the company has strong market awareness since the product was launched and maintained a rapid growth of more than 100% for several consecutive years. In 2021, the sales performance exceeded that of animal and plant probiotics for the first time, and has become the second largest business segment of the company. Affected by the downturn of the breeding industry and the slowdown in the growth of dairy consumption, the sales of animal and plant probiotics and compound food additives have remained basically stable in recent years, and the sales revenue of compound food additives has decreased to a certain extent in 2021. It is expected that in the next 2-3 years, the sales of edible probiotic products will exceed that of compound food additives, and become the business segment with the largest proportion of revenue, the strongest profitability and the most obvious competitive advantage in the market.
(II) main products and uses of the company
(1) Edible probiotic products
The company’s continuous investment and deep cultivation in the field of probiotic R & D gradually shows its competitive advantage in the industry and has accumulated detailed data support. The significant application efficacy of core strains has obvious attraction for food enterprises to develop functional foods and drug manufacturers to develop various dietary supplements. On the basis of eating probiotic products, the company has continuously deepened the research and development and expanded products such as yogurt starter, inactivated probiotic products and metabolites. On the one hand, it has increased the application field of probiotic products and widened the market space of products. On the other hand, it also shows the competitive pattern of product differentiation of the company, which has been well recognized by the market.
The company’s edible probiotic products mainly include food grade probiotic raw material mushroom powder for enterprise customers (used as food ingredients or pet food ingredients) and “yishiyou” brand series probiotic end consumer products for end consumers.
The company has a strain resource bank containing more than 20000 strains of lactic acid bacteria (including probiotics), and has mastered a complete set of technologies for probiotic isolation, screening, evaluation, culture, freeze-drying and preservation. Among them, core strains such as Lactobacillus casei Zhang, Bifidobacterium lactis V9, Lactobacillus plantarum p-8, Bifidobacterium lactis probio-m8 and Streptococcus thermophilus S10 have been widely used in probiotic products and animal and plant probiotics.
Scientific research and experiments have proved that the main functions or functions of these probiotics are as follows:
Strain name strain source main efficacy
Regulate the rejuvenation of human intestinal flora; Prevent upper respiratory tract infection in middle-aged and elderly people; Stabilize the intestinal flora of people of different ages; Slow down kidney disease; Antagonizing intestinal pathogenic bacteria; Improve the immunity of Lactobacillus casei Zhang isolated from Inner Mongolia prairie; Regulate intestinal flora homeostasis; Improve the antioxidant capacity of the body; Regulate the metabolism of blood fermented mare’s milk fat and protect the liver; Improve impaired glucose tolerance and prevent type II diabetes; Prevention and treatment of mastitis; Reduce the risk of tumor and colon cancer; Reduce the flora imbalance caused by antibiotics, etc
Bifidobacterium lactis V9 was isolated from the intestines of healthy Mongolian children, which can effectively treat diarrhea and constipation and improve intestinal flora; Remission of polycystic ovary syndrome (PCOS); Antagonize intestinal pathogenic bacteria and protect diarrhea animals
Improve human intestinal colonization ability and maintain intestinal homeostasis; Relieve stress and anxiety, improve the ability to recognize the natural hair of Lactobacillus plantarum p-8 isolated from Inner Mongolia prairie; Improve lipid metabolism, improve antioxidant capacity and regulate intestinal flora; Fermented milk can improve immunity; Prevent fat deposition, regulate intestinal flora and reduce antibiotic dependence
Bifidobacterium lactis probio-m8 was isolated from breast milk of healthy women to alleviate asthma; Alleviate acute respiratory tract infection in infants; Regulate human immunity; Relieve constipation and anxiety; Improve osteoporosis; Adjuvant therapy for Parkinson’s disease and coronary heart disease
The characteristics of curd are good, and the tissue state of fermented soybean milk is fine and smooth; Streptococcus thermophilus S10 was isolated from Qinghai natural fermented yogurt, and its fermented soybean milk has the unique flavor of soybean milk; It can convert inactive soybean isoflavones into functional active isoflavones
The company’s main edible probiotic products are as follows:
Product name product diagram remarks
Edible probiotic raw material powder can be widely used in fermented milk, milk edible probiotic raw material powder beverage, milk powder, health products, functional food and animal feed.
Yishiyou added strains: Lactobacillus casei Zhang, Bifidobacterium lactis V9, (general version) Lactobacillus plantarum p-8
Instant compound probiotic solid
Body drink
(probiotic end consumer goods) yishiyou
(scavenger) added strains: Lactobacillus casei Zhang, Bifidobacterium lactis B-01
Yishiyou added strains: Lactobacillus casei Zhang, Bifidobacterium lactis V9, (adult) Lactobacillus plantarum p-8
Yishiyou added strains: Bifidobacterium lactis probio-m8, rhamnosus Lactobacillus (children’s powder) probio-m9 and fermented Lactobacillus cect5716
Yishiyou added strains: Lactobacillus casei Zhang, Bifidobacterium lactis V9, (female) Lactobacillus plantarum p-8, Bifidobacterium adolescens kt-a8, Lactobacillus plantarum P-01
Yishiyou added strains: Lactobacillus casei Zhang and Bifidobacterium lactis V9
